Why Moderna Inc (MRNA) Stock Is Rising
As of 2026-10-16, Moderna Inc (MRNA) has a next-year EPS growth estimate of 43.00%. Featured in 6 EPS revision reports, most recently on 2026-10-15.
Why MRNA Stock Is Rising
- +EPS Estimate Upgraded: Analysts raised Moderna Inc's next-year EPS growth estimate from 42.92% to 43.02% on 2026-10-09.
- ·Current-Year Growth: Projected at -14.49%, supporting the forward estimate revision.
News Context
MRNA has risen primarily after analysts slightly raised next-year EPS growth estimates to 43.00% on 2026-10-09. No headline directly explains that revision, though a planned national cancer-vaccine effort and NIH push appear to have supported momentum
Generated 2026-10-16 · news as of 2026-10-16
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 43.00%
- EPS growth this year
- -14.49%
- EPS next quarter (est)
- -$1.09
- Last price
- $218.01
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-10-16 | 43.00% | -14.49% | -$1.09 | $218.01 |
| 2026-10-15 | 43.00% | -14.49% | -$1.09 | $236.50 |
| 2026-10-14 | 43.02% | -14.57% | -$1.10 | $226.30 |
| 2026-10-13 | 43.02% | -14.57% | -$1.10 | $216.25 |
| 2026-10-12 | 43.02% | -14.57% | -$1.10 | $213.74 |
| 2026-10-11 | 43.02% | -14.57% | -$1.10 | $225.00 |
| 2026-10-10 | 43.02% | -14.57% | -$1.10 | $225.00 |
| 2026-10-09 | 43.02% | -14.57% | -$1.10 | $225.00 |
| 2026-10-08 | 42.92% | -14.57% | -$1.10 | $197.00 |
| 2026-10-07 | 42.91% | -14.57% | -$1.10 | $196.48 |
| 2026-10-06 | 43.11% | -14.57% | -$1.10 | $187.46 |
| 2026-10-05 | 43.11% | -14.57% | -$1.10 | $203.21 |
| 2026-10-04 | 43.11% | -14.57% | -$1.10 | $190.01 |
| 2026-10-03 | 43.11% | -14.57% | -$1.10 | $190.01 |
| 2026-10-02 | 43.11% | -14.57% | -$1.10 | $190.01 |
| 2026-10-01 | 43.11% | -14.57% | -$1.10 | $188.94 |
| 2026-09-30 | 43.11% | -14.57% | -$1.10 | $192.57 |
| 2026-09-29 | 43.17% | -14.62% | -$1.10 | $203.46 |
| 2026-09-28 | 43.17% | -14.62% | -$1.10 | $197.28 |
| 2026-09-27 | 43.17% | -14.62% | -$1.10 | $198.88 |
| 2026-09-25 | 43.17% | -14.62% | -$1.10 | $198.88 |
| 2026-09-24 | 43.17% | -14.62% | -$1.10 | $194.82 |
| 2026-09-23 | 42.60% | -14.52% | -$1.10 | $182.11 |
| 2026-09-22 | 42.60% | -14.52% | -$1.10 | $182.56 |
| 2026-09-21 | 42.60% | -14.52% | -$1.10 | $172.94 |
| 2026-09-20 | 42.60% | -14.52% | -$1.10 | $154.04 |
| 2026-09-18 | 42.60% | -14.52% | -$1.10 | $154.04 |
| 2026-09-17 | 42.60% | -14.52% | -$1.10 | $158.07 |
| 2026-09-16 | 42.60% | -14.52% | -$1.10 | $145.62 |
| 2026-09-15 | 42.60% | -14.52% | -$1.10 | $143.77 |
Reports Featuring MRNA
- 2026-10-15
MRNA Jumps 20.1% on EPS Revision and Goldman Upgrade; VRA, WQEY, RGEN Surge
- 2026-10-14
MRNA Jumps 14.9%, NVAX Up 12.7% as Healthcare Stocks Ride EPS Revisions
- 2026-07-07
WBX +40.8% Leads EPS Revision Winners; NMAX Surges on 217.8pp EPS Upgrade
- 2026-07-06
Stock Surge Alert: WBX +47%, IOT +29%, MRNA +22% on EPS Revisions
- 2026-07-02
Top Stock Gainers Driven by EPS Estimate Revisions: QNRX Up 40.9%, IOT Up 24% - July 2, 2026
- 2026-07-01
Top EPS Revision-Driven Movers: QNRX Surges +44.9% as NMAX Sees 376.9% Growth Estimate
Recent News
- MRNA Stock Sets New 52-Week High As Nasdaq-100 Reentry Meets NIH Cancer-Vaccine PushStocktwits
- Flu season is already here. Here's what to know about this year's flu shots.MarketWatch
- Moderna stock jumps on planned national cancer vaccine effortYahoo Finance
- Moderna, Eli Lilly Lead Healthcare Stocks Higher on a Down Day for MarketsInvestopedia
- CPHI 2026: Moderna builds on its COVID-era manufacturing lessonsPharmaceutical Technology
- Novavax and Moderna Shares Fall as Citi Assesses Vaccine Sector VolatilityInvestorsHub
- Pandemic Panic Is Back on Wall Street. What to Know About the Russian Plague Scare.Barrons.com
- Novavax, Moderna stocks fall after WHO calls plague risk 'low'Yahoo Finance
- Biotech Stocks Tumble, With Recent Winners Moderna, Vaxcyte Among The Biggest LosersInvestor's Business Daily
- NVAX, EBS, ARCT, MRNA Rally After Russia Plague Lab Worker's Death: Retail Traders Eye 'Contract Awards'Stocktwits
Screen Performance
Aggregate stats across all 2082 tickers our top-EPS-revision screen has flagged over the past 198 days.
- Median return since detection
- -3.0%
- % of tickers in the green
- 43%
- Median return on winners
- +21.5%
- Large revisions captured
- 1886
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
Why did Moderna Inc (MRNA) stock go up recently?▾
Moderna Inc (MRNA) stock has risen following an analyst upgrade of its next-year EPS growth estimate from 42.92% to 43.02% on 2026-10-09. EPS estimate upgrades are among the strongest leading indicators of stock outperformance.
What is Moderna Inc's next-year EPS growth estimate?▾
As of 2026-10-16, Moderna Inc (MRNA) has a next-year EPS growth estimate of 43.00%, based on analyst consensus.
When was the latest EPS estimate revision for MRNA?▾
The most recent revision occurred on 2026-10-15, when analysts adjusted the next-year EPS growth estimate from 43.02% to 43.00%.
What sector and industry does Moderna Inc belong to?▾
Moderna Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. MRNA appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Moderna Inc (MRNA) appears here because it was detected by our daily top-EPS-revision-performer screen.